You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 21, 2024

CLINICAL TRIALS PROFILE FOR XEMBIFY

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for XEMBIFY

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05645107 ↗	A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobulinemia and Recurrent or Severe Infections Associated	Not yet recruiting	Grifols Therapeutics LLC	Phase 3	2022-12-17	The primary purpose of the study is to evaluate whether weekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in participants with hypogammaglobulinemia (HGG) associated with B-cell chronic lymphocytic leukemia (CLL) in comparison to the Placebo plus SMT group.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for XEMBIFY

Condition Name

Chart
Table

Condition Name for XEMBIFY
Intervention	Trials
B-cell Chronic Lymphocytic Leukemia	1
Bacterial Infections	1
Hypogammaglobulinemia	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for XEMBIFY
Intervention	Trials
Bacterial Infections	1
Agammaglobulinemia	1
Leukemia, Lymphoid	1
Leukemia, Lymphocytic, Chronic, B-Cell	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for XEMBIFY

Trials by Country

Map
Table

Trials by Country for XEMBIFY
Location	Trials
United States	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for XEMBIFY
Location	Trials
Pennsylvania	1
Ohio	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for XEMBIFY

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for XEMBIFY
Clinical Trial Phase	Trials
Phase 3	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for XEMBIFY
Clinical Trial Phase	Trials
Not yet recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for XEMBIFY

Sponsor Name

Chart
Table

Sponsor Name for XEMBIFY
Sponsor	Trials
Grifols Therapeutics LLC	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for XEMBIFY
Sponsor	Trials
Industry	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.